---
title: 38,000 Reasons to Rethink Toxicity Testing
description: Discover how high-throughput, human-relevant solutions can streamline early drug safety assessment.
---
[](https://www.moleculardevices.com/)
# 38,000 Reasons to rethink
# toxicity testing
[Speak to specialist](https://info.moleculardevices.com/dd/flipr/toxicity-testing#requestquote)
## Streamline early drug safety with high-throughput, human-relevant solutions
Toxicity is one of the leading causes of drug candidate failure—accounting for up to 30% of clinical trial terminations and billions in lost investment. Relying on outdated animal models and manual workflows often leads to late-stage surprises, increased costs, and delayed delivery of safer therapies to patients. What’s more, growing regulatory pressure and ethical concerns are driving the need for faster, more predictive, and human-relevant toxicity assessment.
That’s why it’s time to rethink toxicity testing. With our advanced, end-to-end solutions—centered around the FLIPR Penta High-Throughput Cellular Screening System—you can identify toxicity risks earlier, streamline your workflows, and reduce reliance on animal testing. Empower your teams to make faster, data-driven decisions and bring safer therapeutics to market sooner.
The end-to-end toxicity testing workflow above combines real-time functional screening with morphological and viability analysis to deliver a complete view of compound effects. Starting with the addition of FLIPR Calcium 6 Dye and compound treatment, functional responses are captured using the FLIPR Penta System and analyzed with ScreenWorks Peak Pro 2 Software. Cells are then stained and imaged on the ImageXpress HCS.ai system, with data acquired via MetaXpress Acquire and analyzed using IN Carta Software. The result is a streamlined, scalable workflow that integrates kinetic, structural, and AI-driven insights for more predictive toxicity assessment.
#### Human-relevant models
Animal models can’t fully replicate human biology—leading to false positives, regulatory delays, and clinical trial failures. Our solutions integrate human iPSC-derived cardiomyocytes and neurons, offering more predictive, physiologically relevant data to assess cardiotoxicity and neurotoxicity at the earliest stages.
#### High-throughput screening with FLIPR Penta
Traditional compound screening is slow, manual, and inefficient. The FLIPR Penta System accelerates your workflow, allowing you to screen up to 38,000 compounds per day with real-time calcium oscillation analysis—enabling faster, data-driven decisions and reducing time-to-market.
#### AI-powered data insights
Toxicity testing generates complex, multi-dimensional datasets. With our IN Carta Image Analysis Software, you can simplify image analysis, automate data processing, and leverage AI-driven insights to detect subtle phenotypic changes—reducing analysis time and human error.
#### Comprehensive, validated assay kits
Inconsistent protocols and non-standardized reagents can compromise data integrity. Our EarlyTox Assay Kit provides ready-to-use, validated solutions for efficient, reproducible toxicity testing—so you can trust your results and meet regulatory expectations.
## Transform your toxicity testing workflow
By integrating high-throughput screening, human-relevant models, AI-powered data analysis, and validated assay kits, we help you:
- Reduce reliance on animal testing
- Identify toxicity risks earlier in the drug discovery process
- Streamline workflows and minimize operational costs
- Improve reproducibility and regulatory alignment
### I want to learn more
## Witness how researchers are advancing toxicity testing with the FLIPR System
StemoniX set out to overcome the limitations of traditional 2D and animal-based neuroscience models by developing microBrain® 3D, a platform of highly uniform, human iPSC-derived neural spheroids. To evaluate functional neurotoxicity in these more predictive models, they turned to the FLIPR Tetra system, which allowed their team to capture real-time neuronal activity across thousands of wells, providing high-throughput, kinetic data that reflected true human physiology.
With this approach, StemoniX was able to accelerate neurotoxicity screening while improving the relevance and reliability of their results.
## Take a closer look: see the FLIPR Penta in action
This virtual demo shows how the FLIPR Penta High-Throughput Cellular Screening System supports real-time, kinetic screening using advanced assay kits and intuitive software.
From set-up to data analysis, get a firsthand look at how the system handles large compound libraries, captures functional cellular responses, and helps researchers make confident decisions earlier in the drug discovery process.
## We empower scientists to advance discovery
## We're a trusted life sciences partner to researchers around the world
*\*Price, time to deliver, and specifications will vary based on mutually agreed technical requirements. Solution requirements may cause adjustment to standard performance.*
-
-
-
-
©2026 Molecular Devices, LLC. All rights reserved.
- [Terms & Conditions](https://www.moleculardevices.com/terms-and-conditions)
- [Privacy Policy](https://www.moleculardevices.com/privacy)
- [Do Not Sell or Share My Data](https://www.moleculardevices.com/california-consumer-rights-notice)
- [Online Terms of Use](https://www.moleculardevices.com/online-terms-use)
- [Trademarks](https://www.moleculardevices.com/trademarks)
- [Careers](https://jobs.danaher.com/global/en/molecular-devices)
- [Support](https://www.moleculardevices.com/service-support)
- [Contact Us](https://www.moleculardevices.com/contact)
- [Sitemap](https://www.moleculardevices.com/sitemap)
- [Danaher Life Sciences](https://lifesciences.danaher.com/)
[](https://www.danaher.com/)